SS-31 + Cardiogen

Tipo de evidencia

Estudio preclínico

Cardiogen component preclinical tissue-culture evidence

Publicación y hallazgo principal

[The effect of the amino acids and cardiogen on the development of myocard tissue culture from young and old rats].

In myocardial tissue cultures from young and aged rats, Cardiogen and selected amino acids increased cellular proliferation.

Advances in gerontology = Uspekhi gerontologii

Fuente

PMID 20210190 · 2009

Tipo de evidencia

Estudio aleatorizado en humanos

SS-31 component randomized human evidence

Publicación y hallazgo principal

Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.

In the randomized MMPOWER-3 trial, elamipretide was well tolerated but did not improve six-minute walk distance or fatigue scores versus placebo at 24 weeks.

Neurology

Fuente

PMID 37268435 · 2023

Tipo de evidencia

Estudio preclínico

Cardiogen component preclinical evidence

Publicación y hallazgo principal

Tumor-modifying effect of cardiogen peptide on M-1 sarcoma in senescent rats.

In senescent rats bearing M-1 sarcoma, Cardiogen administration was associated with higher tumour-cell apoptosis than control treatment.

Bulletin of experimental biology and medicine

Fuente

PMID 20396706 · 2009

Tipo de evidencia

Estudio preclínico

SS-31 component preclinical neuroprotection evidence

Publicación y hallazgo principal

Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice.

In mice, elamipretide reduced mitochondrial dysfunction, oxidative stress and neuroinflammation while improving synaptic structure, learning and memory after lipopolysaccharide exposure.

Journal of neuroinflammation

Fuente

PMID 31747905 · 2019